Lowering the prophylactic platelet transfusion threshold: A prospective analysis

Leukemia and Lymphoma

Volumn 41, Issue 1-2, 2001, Pages 67-76

  Lawrence, J B ^a   Yomtovian, R A ^a   Hammons, T ^a   Masarik, S R ^a   Chongkolwatana, V ^a   Creger, R J ^a   Manka, A ^a   Lazarus, H M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood marrow transplant; Hemorrhage; Leukemia; Platelet transfusion; Thrombocytopenia

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; PENICILLIN G;

ACUTE LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHRONIC LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENDER; HEMATOLOGY; HUMAN; HUMAN CELL; INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIPLE MYELOMA; NEUTROPENIA; ONCOLOGY; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SAFETY; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035068031     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057955     Document Type: Article

References (48)

1. Causes of death in acute leukemia
2. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study
3. A notable change in mortality of aplastic anemia observed during the 1970s in Japan
4. Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: Pro
5. Bone marrow transplantation
6. Platelet utilization in a university hospital
7. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients
8. Platelet transfusion: The 20,000/μl trigger
9. Controversies in transfusion medicine. Prophylactic platelet transfusion revisited after 25 years: Con
10. Platelet transfusion therapy
11. Septic reactions to platelet transfusions. A persistent problem
12. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets
13. Platelet transfusion requirements of children with newly diagnosed lymphoblastic leukaemia
14. Indications for platelet transfusion in children with acute leukemia
15. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy
16. Platelet transfusion therapy
17. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia
18. An audit of the use of platelet concentrates in the prophylaxis of thrombocytopenic haemorrhage in a large haematology unit
19. Therapeutic support of the patient with thrombocytopenia
20. Platelet transfusion
21. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL
22. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
23. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia
24. Optimal dosing and triggers for prophylactic use of platelet transfusions
25. Trigger factors for prophylactic platelet transfusion
26. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/μL versus 20,000/μL
27. Platelet prophylaxis in acute non-lymphoblastic leukaemia
28. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study
29. 9/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
30. Reliability of automated platelet counts: Comparison with manual method and utility for prediction of clinical bleeding
31. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia
32. Effectiveness of platelet transfusion in leukemia and aplastic anemia
33. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution
34. Platelet use in pediatric oncology: A review of 393 transfusions
35. Soluble vascular endothelial growth factor in various blood transfusion components
36. Platelet transfusion for the cancer patient
37. Serum polysaccharide and fever in thrombocytopenic bleeding of leukemia
38. The hemostatic defect produced by carbenicillin
39. Defective platelet function following the administration of penicillin compounds
40. Beta-lactam antibiotics inhibit agonist-stimulated platelet calcium influx
41. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion
42. Amphotericin B-induced injury in stored human platelets
43. Amphotericin B and platelet transfusion
44. Clinical factors influencing the efficacy of pooled platelet transfusions
45. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates
46. Factors influencing 20-hour increments after platelet transfusion
47. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization
48. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis